Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 1/20 | 0.45 |
| ▸ | CALCRL | Q16602 | 16/20 | 0.44 |
| ▸ | RAMP1 | O60894 | 6/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.41 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5387411 | 1.00 | CALCA (0.45) | CALCACALCRLRAMP1CHRM4L3MBTL3 | |
| SCHEMBL5372064 | 0.89 | CALCRL (0.45) | CALCACALCRLRAMP1CHRM4 | |
| SCHEMBL5372060 | 0.89 | CALCRL (0.45) | CALCACALCRLRAMP1CHRM4 | |
| SCHEMBL5378912 | 0.89 | CALCRL (0.46) | CALCACALCRLRAMP1CHRM4 | |
| SCHEMBL5378904 | 0.89 | CALCRL (0.46) | CALCACALCRLRAMP1CHRM4 | |
| SCHEMBL5387598 | 0.88 | CHRM4 (0.47) | CALCACALCRLRAMP1CHRM4 | |
| SCHEMBL5387605 | 0.88 | CHRM4 (0.47) | CALCACALCRLRAMP1CHRM4 | |
| SCHEMBL5378790 | 0.86 | HSD11B1 (0.46) | CALCACALCRLRAMP1CHRM4 | |
| SCHEMBL5378799 | 0.86 | HSD11B1 (0.46) | CALCACALCRLRAMP1CHRM4 | |
| SCHEMBL5371686 | 0.86 | CALCA (0.46) | CALCACALCRLRAMP1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | claimed |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | CALCA 9/4885CALCRL 4/4885RAMP1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.